Skip to content

Hydromorphone in Interscalene Brachial Plexus Block: A Clinical Evaluation of Anesthetic Efficacy and Postoperative Analgesia

Impact of Chloroprocaine Combined with Hydromorphone CGPA on Elderly Patients in Hip Arthroplasty Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116403
Enrollment
Unknown
Registered
2026-01-09
Start date
2026-01-15
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early postoperative pain

Interventions

C group:Brachial plexus block with 20 ml of 2% chloroprocaine.
CH group:Brachial plexus block with 20 ml of 2% chloroprocaine and 0.5 mg of hydromorphone.
H group:Brachial plexus block with 20 ml of hydromorphone 0.5 mg.

Sponsors

The Third People's Hospital of Hefei
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 65 Years

Inclusion criteria

Inclusion criteria: Patients with ASA I-II classification undergoing elective upper limb fracture internal fixation surgery.

Exclusion criteria

Exclusion criteria: Patients aged >=65 years; patients who refuse nerve block; those with coagulation disorders; those who are allergic to chloroprocaine, hydromorphone, or other local anesthetics; those with severe hepatic or renal insufficiency; pregnant or lactating women; those with severe cardiovascular, cerebrovascular, or pulmonary diseases; and those with a history of opioid dependence.

Design outcomes

Primary

MeasureTime frame
The onset time of sensory block;The onset time of motor block;Duration of sensory block;Duration of motor block;

Secondary

MeasureTime frame
Duration surgery;The dosage of propofol;The dosage of sufentanil;The dosage of remifentanil;The incidence of nausea;The incidence of vomiting;The incidence of hypotension;The incidence of hypotension;

Countries

China

Contacts

Public ContactLeiJing Shang

The Third People's Hospital of Hefei

452679851@qq.com+86 159 5547 0909

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026